Ibandronate in the treatment of postmenopausal osteoporosis: A cost-effectiveness analysis in the UK

被引：0
|
作者：
Earnshaw, S.
Lynch, N. O.
Cowell, W.
Beard, S.
机构：
[1] Roche Pharmaceut, London, England
[2] RTI Hlth Solut, Manchester, Lancs, England
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2006年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页码：416 / 416
页数：1
相关论文
共 50 条
  • [41] BISPHOSPHONATES FOR OSTEOPOROSIS TREATMENT: A COST-EFFECTIVENESS ANALYSIS IN VIETNAMESE WOMAN
    Pham, N. H.
    Nguyen, T. B.
    Le, H. P.
    Pham, D. T.
    Ho-Pham, L. T.
    Duong, T. D.
    Nguyen, T., V
    VALUE IN HEALTH, 2017, 20 (09) : A535 - A535
  • [42] A Systematic Review of Cost-Effectiveness Analyses of Drugs for Postmenopausal Osteoporosis
    Hiligsmann, Mickael
    Evers, Silvia M.
    Ben Sedrine, Wafa
    Kanis, John A.
    Ramaekers, Bram
    Reginster, Jean-Yves
    Silverman, Stuart
    Wyers, Caroline E.
    Boonen, Annelies
    PHARMACOECONOMICS, 2015, 33 (03) : 205 - 224
  • [43] Cost-Effectiveness of Different Screening Strategies for Osteoporosis in Postmenopausal Women
    Nayak, Smita
    Roberts, Mark S.
    Greenspan, Susan L.
    ANNALS OF INTERNAL MEDICINE, 2011, 155 (11) : 751 - U176
  • [44] Cost-effectiveness of antiosteoporosis strategies for postmenopausal women with osteoporosis in China
    Li, Na
    Zheng, Bin
    Liu, Maobai
    Zhou, Haimei
    Zhao, Lingfen
    Cai, Hongfu
    Huang, Jingze
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2019, 26 (08): : 906 - 914
  • [45] Cost-effectiveness of romosozumab for the treatment of postmenopausal women with osteoporosis at high risk of fracture in Belgium
    Gielen, Evelien
    Aldven, Martina
    Kanis, John A.
    Borgstrom, Fredrik
    Senior, Emmanuelle
    Willems, Damon
    OSTEOPOROSIS INTERNATIONAL, 2024, 35 (07) : 1173 - 1183
  • [46] EFFICIENCY AND SAFETY OF IBANDRONATE IN TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
    Gojkovic, F.
    Vasic, J.
    Elez, J.
    Vojinovic, V. Culafic
    Zvekic-Svorcan, J.
    OSTEOPOROSIS INTERNATIONAL, 2015, 26 : S169 - S169
  • [47] Ibandronate IV injection is cost-effective in the treatment of UK women with postmenopausal osteoporosis who are intolerant to oral bisphosphonates
    Lynch, N. O.
    Earnshaw, S.
    Graham, C.
    Patroe, V.
    Boisdron, J.
    Middelhoven, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 529 - 529
  • [48] Intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis
    Thiebaud, D
    Kriegbaum, H
    Huss, H
    Christiansen, C
    Burckhardt, P
    OSTEOPOROSIS 1996, 1996, 1118 : 321 - 325
  • [49] Ibandronate: An IV injection for the treatment for postmenopausal osteoporosis
    Rizzoli, Rene
    Reid, David M.
    BONE, 2007, 41 (05) : S24 - S28
  • [50] COST-EFFECTIVENESS OF ZOLEDRONIC ACID VERSUS ALENDRONIC ACID IN THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL EGYPTIAN PATIENTS: DECISION ANALYSIS
    Elmansy, H.
    Metry, A. B.
    Eldessouki, R.
    Elsisi, G.
    VALUE IN HEALTH, 2015, 18 (07) : A646 - A646
12345